Last reviewed · How we verify

MIL62 — Competitive Intelligence Brief

MIL62 (MIL62) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-6 receptor antagonist monoclonal antibody. Area: Immunology.

phase 3 IL-6 receptor antagonist monoclonal antibody IL-6R (Interleukin-6 receptor) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

MIL62 (MIL62) — Beijing Mabworks Biotech Co., Ltd.. MIL62 is a monoclonal antibody targeting IL-6 receptor to inhibit interleukin-6 signaling and reduce inflammatory responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MIL62 TARGET MIL62 Beijing Mabworks Biotech Co., Ltd. phase 3 IL-6 receptor antagonist monoclonal antibody IL-6R (Interleukin-6 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-6 receptor antagonist monoclonal antibody class)

  1. Beijing Mabworks Biotech Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MIL62 — Competitive Intelligence Brief. https://druglandscape.com/ci/mil62. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: